Absci Dividends and Buybacks

Dividend criteria checks 0/6

Absci does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-28.8%

Buyback Yield

Total Shareholder Yield	-28.8%
Future Dividend Yield	0%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile

Oct 03

Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships

Jul 28

Is Absci (NASDAQ:ABSI) A Risky Investment?

Jun 17

Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula

May 16

Absci: Differentiated Antibody Discovery Play

Feb 27

Absci GAAP EPS of -$0.32 misses by $0.01, revenue of $1M misses by $0.68M

Aug 11

Absci teams up to help develop antibody drugs for cancer

Jul 07

Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out

Jan 10

IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)

Jul 22

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ABSI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABSI's dividend payments have been increasing.

Dividend Yield vs Market

Absci Dividend Yield vs Market

How does ABSI dividend yield compare to the market?
Segment	Dividend Yield
Company (ABSI)	n/a
Market Bottom 25% (US)	1.3%
Market Top 25% (US)	4.2%
Industry Average (Biotechs)	2.3%
Analyst forecast (ABSI) (up to 3 years)	0%

Notable Dividend: Unable to evaluate ABSI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABSI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ABSI's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ABSI has not reported any payouts.

Absci Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Absci Corporation: Struggling To Live Up To Its AI Promise

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Is Absci (NASDAQ:ABSI) A Risky Investment?

Absci: Embryonic Pipeline Looks Expensive Relative To Peers

Absci Corporation to Report Q3, 2024 Results on Nov 12, 2024

Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships

Absci Corporation to Report Q2, 2024 Results on Aug 14, 2024

Is Absci (NASDAQ:ABSI) A Risky Investment?

Chief Business Officer & CFO notifies of intention to sell stock

Chief Business Officer & CFO notifies of intention to sell stock

Consensus revenue estimates decrease by 26%

Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Absci Corporation to Report Q1, 2024 Results on May 14, 2024

Consensus revenue estimates fall by 20%

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates decrease by 13%

New minor risk - Shareholder dilution

Absci Corporation has filed a Follow-on Equity Offering in the amount of $75 million.

Absci Corporation has filed a Follow-on Equity Offering in the amount of $75 million.

Absci: Differentiated Antibody Discovery Play

Absci Initiates IND-Enabling Studies for Abs-101, A Potential Best-In-Class Anti-Tl1a Antibody De Novo Designed and Optimized Using Generative Ai

Absci Corporation to Present Preclinical Data for ABS-101, A Potential Best-In-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference

Absci Corporation Appoints Menelas Pangalos as Class II Director and Member of Compensation Committee of the Board, Effective January 1, 2024

Price target decreased by 14% to US$5.76

Consensus revenue estimates decrease by 42%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 15% to US$5.50

Consensus EPS estimates fall by 21%, revenue upgraded

Absci Corporation Announces Resignation of Sarah Korman as Chief Legal Officer and Interim Chief Business Officer, Effective as of September 15, 2023

Absci Corporation Appoints Zach Jonasson as Chief Business Officer, Effective from August 31, 2023

Absci Corporation Reports Impairment Results for the Second Quarter Ended June 30, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Absci Corporation and California Institute of Technology Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development

New major risk - Share price stability

Absci Corporation Appoints Frans Van Houten to Its Board of Directors

Price target decreased by 10% to US$7.73

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Casdin Capital Engages in Discussions with Absci Corporation

Price target decreased by 28% to US$8.60

Consensus revenue estimates decrease by 23%, EPS upgraded

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Casdin Capital Engages in Discussions with Absci Corporation

Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation

Absci Corporation Announces Ability to Create and Validate de novo Antibodies in Silico with Use of Zero-Shot Generative AI

Consensus forecasts updated

Price target decreased to US$12.10

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Absci Corporation Appoints Dan Rabinovitsj as Newest Member of its Board of Directors

Chief Financial Officer exercised options to buy US$155k worth of stock.

Absci Corporation Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer

Absci Corporation Announces End of Nikhil Goel as Chief Strategy Officer

Price target decreased to US$13.10

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Absci GAAP EPS of -$0.32 misses by $0.01, revenue of $1M misses by $0.68M

Eli Casdin Resigns from Board of Directors of Absci Corporation

Absci teams up to help develop antibody drugs for cancer

Absci Corporation(NasdaqGS:ABSI) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Consensus EPS estimates fall by 29%

Consensus revenue estimates fall by 17%

Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$0.33 loss per share

Absci, CORP has completed an IPO in the amount of $200 million.

IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies